The role of human drug self-administration procedures in the development of medications

Drug and Alcohol Dependence

Volumn 96, Issue 1-2, 2008, Pages 1-15

  Comer, S D ^a   Ashworth, J B ^b   Foltin, R W ^a   Johanson, C E ^c   Zacny, J P ^d   Walsh, S L ^e  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b GRÜNENTHAL GMBH   (Germany)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Abuse liability; Abuse deterrent formulation; Drug self administration; Human

Indexed keywords

ADROGOLIDE; BACLOFEN; BUPRENORPHINE; BUTORPHANOL; DEPOTREX; DESIPRAMINE; DIAMORPHINE; ECOPIPAM; ELI 216; ENADOLINE; FLUPENTIXOL; GABAPENTIN; HYDROMORPHONE; LISDEXAMFETAMINE; MEMANTINE; METHADONE; MODAFINIL; MORPHINE SULFATE; NALTREXONE; NRP 290; OPIATE; OXYCODONE; PERGOLIDE; PHENYTOIN; PLACEBO; PTI 202; TQ 1017; TRAMADOL; VYNASE;

COCAINE DEPENDENCE; CONDITIONING; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG RESEARCH; DRUG SELF ADMINISTRATION; HUMAN; OPIATE ADDICTION; PREDICTIVE VALIDITY; PRIORITY JOURNAL; QUESTIONNAIRE; REINFORCEMENT; REVIEW; SELF REPORT; SUBSTANCE ABUSE;

CHOICE BEHAVIOR; COCAINE-RELATED DISORDERS; CONDITIONING, OPERANT; DRUG DESIGN; DRUG EVALUATION; DRUG INTERACTIONS; HUMANS; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PHARMACEUTICAL PREPARATIONS; REINFORCEMENT (PSYCHOLOGY); REINFORCEMENT SCHEDULE; SELF ADMINISTRATION; STREET DRUGS; SUBSTANCE-RELATED DISORDERS;

EID: 43449118951     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2008.03.001     Document Type: Review

References (116)

1. Abreu M.E., Bigelow G.E., Fleisher L., and Walsh S.L. Effect of intravenous injection speed on responses to cocaine and hydromorphone in humans. Psychopharmacology 154 (2001) 76-84
2. Altman J.L., Meyer R.E., Mirin S.M., McNamee, and McDougle H.B. Opiate antagonists and the modification of heroin self-administration behavior in man: an experimental study. Int. J. Addict. 11 (1976) 485-499
3. Amass L., Bickel W.K., Crean J.P., Blake J., and Higgins S.T. Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans. Psychopharmacology 136 (1998) 217-225
4. Arnold J.M., and Roberts D.C.S. A critique of fixed and progressive ratio schedules used to examine the neural substrates of drug reinforcement. Pharmacol. Biochem. Behav. 57 3 (1997) 441-447
5. Ator N.A., and Griffiths R.R. Principles of drug abuse liability assessment in laboratory animals. Drug Alcohol Depend. 70 (2003) S55-S72
6. Balster R.L., and Bigelow G.E. Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend. 70 (2003) S13-S40
7. Barrett A.C., Negus S.S., Mello N.K., and Caine S.B. Effect of GABA agonists and GABA-A receptor modulators on cocaine- and food-maintained responding and cocaine discrimination in rats. J. Pharmacol. Exp. Ther. 315 (2005) 858-871
8. Bigelow G., Griffiths R., and Liebson I. Experimental human drug self-administration: methodology and application to the study of sedative abuse. Pharmcol. Rev. 27 4 (1976) 523-531
9. Collins E.D., Vosburg S.K., Ward A.S., Haney M., and Foltin R.W. Memantine increases cardiovascular but not behavioral effects of cocaine in methadone-maintained humans. Pharmacol. Biochem. Behav. 83 1 (2006) 47-55
10. Comer, S.D., Ashworth, J.B., in press. The growth of prescription opioid abuse, in: Passik, S. (Ed.), Pain and Chemical Dependency.
11. Comer S.D., and Collins E.D. Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers. J. Pharmacol. Exp. Ther. 303 (2002) 694-703
12. Comer S.D., Collins E.D., and Fischman M.W. Buprenorphine sublingual tablets: effects on IV heroin self-administration by humans. Psychopharmacology 154 (2001) 28-37
13. Comer S.D., Collins E.D., and Fischman M.W. Intravenous buprenorphine self-administration by detoxified heroin abusers. J. Pharmacol. Exp. Ther. 301 (2002) 266-276
14. Comer S.D., Collins E.D., Kleber H.D., Nuwayser E.S., Kerrigan J.H., and Fischman M.W. Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Psychopharmacology 159 (2002) 351-360
15. Comer S.D., Sullivan M.A., and Walker E.A. Comparison of intravenous buprenorphine and methadone self-administration by recently detoxified heroin-dependent individuals. J. Pharmacol. Exp. Ther. 315 (2005) 1320-1330
16. Comer S.D., Sullivan M.A., Whittington R.A., Vosburg S.K., and Kowalczyk W.J. Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers. Neuropsychopharmacology 33 (2008) 1179-1191
17. Comer S.D., Walker E.A., and Collins E.D. Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers. Psychopharmacology 181 (2005) 664-675
18. Comer S.D., and Zacny J.P. Subjective effects of opioids. In: Earleywine M. (Ed). Mind-altering Drugs: The Science of Subjective Experience (2005), Oxford University Press, New York 217-239
19. Cone E.J. Ephemeral profiles of prescription drug and formulation tampering: evolving pseudoscience on the Internet. Drug Alcohol Depend. 83 Suppl. 1 (2006) S31-S39
20. Dackis C.A., Kampman K.M., Lynch K.G., Pettinati H.M., and O'Brien C.P. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 30 (2005) 205-211
21. Deneau G.E., Yanagita T., and Seevers M. Self-administration of psychoactive substances by the monkey-a measure of psychological dependence. Psychopharmacology (Berl) 16 (1969) 30-48
22. de Wit H., and Chutuape M.A. Increased ethanol choice in social drinkers following ethanol preload. Behav. Pharmacol. 4 1 (1993) 29-36
23. de Wit H., Dudish S., and Ambre J. Subjective and behavioral effects of diazepam depend on its rate of onset. Psychopharmacology (Berl) 112 2/3 (1993) 324-330
24. Donny E.C., Brasser S.M., Bigelow G.E., Stitzer M.L., and Walsh S.L. Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. Addiction 100 (2005) 1496-1509
25. Drug Abuse Warning Network, 2005. National Estimates of Drug-Related Emergency Department Visits, DAWN Series D-29, DHHS Publication No. (SMA) 07-4256, Rockville, MD, March 2007.
26. Evans S.M., Walsh S.L., Levin F.R., Foltin R.W., Fischman M.W., and Bigelow G.E. The effects of flupenthixol on the subjective and cardiovascular effects of intravenous cocaine in humans. Drug Alcohol Depend. 64 (2001) 271-283
27. Faggiano F., Vigna-Taglianti F., Versino E., and Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst. Rev. 3 (2003) CD002208
28. B receptor antagonist, agonists and allosteric positive modulator on the cocaine-induced self-administration and drug discrimination. Eur. J. Pharmacol. 574 (2007) 148-157
29. Fischman M.W., Foltin R.W., Nestadt G., and Pearlson G.D. Effects of desipramine maintenance on cocaine self-administration by humans. J. Pharmacol. Exp. Ther. 253 2 (1990) 760-770
30. Foltin R.W., and Fischman M.W. Assessment of abuse liability of stimulant drugs in humans: a methodological survey. Drug Alcohol Depend. 28 (1991) 3-48
31. Foltin R.W., and Fischman M.W. Effects of buprenorphine on the self-administration of cocaine by humans. Behav. Pharmacol. 5 (1994) 78-89
32. Gorski, T.T., 2002. Oxycontin-Manufacturer plans for a safer pain medication. http://www.tgorski.com/drug_updates/OxyContin-Manufactures Plan For A Safer Pain Medication 010808.htm. Accessed July 9, 2007.
33. Greenwald M.K., Johanson C.E., and Schuster C.R. Opioid reinforcement in heroin-dependent volunteers during outpatient buprenorphine maintenance. Drug Alcohol Depend. 56 (1999) 191-203
34. Greenwald M.K., Schuh K.J., Hopper J.A., Schuster C.R., and Johanson C.E. Effects of buprenorphine sublingual tablet maintenance on opioid drug-seeking behavior by humans. Psychopharmacology 160 (2002) 344-352
35. Griffiths R.R., Bigelow G.E., and Ator N.A. Principles of initial experimental drug abuse liability assessment in humans. Drug Alcohol Depend. 70 (2003) S41-S54
36. Griffiths R.R., Bigelow G.E., and Liebson I.A. Facilitation of human tobacco self-administration by ethanol: a behavioral analysis. J. Exp. Anal. Behav. 25 (1976) 279-292
37. Griffiths R.R., Bigelow G.E., Liebson I.A., and Kaliszak J.E. Drug preference in humans: double-blind choice comparison of pentobarbital, diazepam, and placebo. J. Pharmacol. Exp. Ther. 215 3 (1980) 649-661
38. Griffiths R.R., Bigelow G.E., and Liebson I.A. Human coffee drinking: reinforcing and physical dependence producing effects of caffeine. J. Pharmacol. Exp. Ther. 239 (1986) 416-425
39. Griffiths R.R., Troisi J.R., Silverman K., and Mumford G.K. Multiple-choice procedure: an efficient approach for investigating drug reinforcement in humans. Behav. Pharmacol. 4 (1993) 3-13
40. Grudzinskas C., Balster R.L., Gorodetzky C.W., Griffiths R.R., Henningfield J.E., Johanson C.E., Mansbach R.S., McCormick C.G., Schnoll S.H., Strain E.C., and Wright C. Impact of formulation on the abuse liability, safety and regulation of medications: the expert panel. Drug Alcohol Depend. 83S (2006) S77-S82
41. Haney M., Collins E.D., Ward A.S., Foltin R.W., and Fischman M.W. Effect of a selective dopamine D1 agonist (ABT-431) on smoked cocaine self-administration in humans. Psychopharmacology 143 (1999) 102-110
42. Haney M., Foltin R.W., and Fischman M.W. Effects of pergolide on intravenous cocaine self-administration in men and women. Psychopharmacology 137 (1998) 15-24
43. Haney M., Hart C.L., and Foltin R.W. Effects of baclofen on cocaine self-administration: opioid- and nonopioid-dependent volunteers. Neuropsychopharmacology 31 8 (2006) 1814-1821
44. Haney, M., Spealman, R., in press. Controversies in translational research: drug self-administration. Psychopharmacology.
45. Haney M., Ward A.S., Foltin R.W., and Fischman M.W. Effects of ecopipam, a selective D1 antagonist, on smoke cocaine self-administration by humans. Psychopharmacology 155 (2001) 330-337
46. Hart C.L., Haney M., Vosburg S.K., Rubin E., and Foltin R.W. Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacology 33 (2008) 761-768
47. Hart C.L., Ward A.S., Collins E.D., Haney M., and Foltin R.W. Gabapentin maintenance decreases smoked cocaine-related subjective effects, but not self-administration by humans. Drug Alcohol Depend. 73 (2004) 279-287
48. Heins, J., 2002. Purdue Pharma provides update on development of new abuse-resistant pain medications-FDA cites patient needs as first priority, New Drug Application delayed. http://www.purduepharma.com/pressroom/news/oxycontinnews/20020618.htm. Accessed July 9, 2007.
49. Henningfield J.E., Cohen C., and Heishman S.J. Drug self-administration methods in abuse liability evaluation. Br. J. Addict. 86 (1991) 1571-1577
50. Henningfield J.E., and Goldberg S.R. Control of behavior by intravenous nicotine injections in human subjects. Pharmacol. Biochem. Behav. 19 (1983) 1021-1026
51. Higgins S.T., Bickel W.T., and Hughes J.R. Influence of an alternative reinforcer on human cocaine self-administration. Life Sci. 55 3 (1994) 179-187
52. Hodos W. Progressive-ratio as a measure of reward strength. Science 134 (1961) 943-944
53. Hodos W., and Kalman G. Effects of increment size and reinforcer volume on progressive-ratio performance. J. Exp. Anal. Behav. 6 (1963) 387-392
54. Jasinski D.R., Pevnick J.S., and Griffith J.D. Human pharmacology and abuse potential of the analgesic buprenorphine. Arch. Gen. Psychiatry 35 (1978) 01-516
55. Johanson C.E., and Uhlenhuth E.H. Drug preference and mood in humans: diazepam. Psychopharmacology 71 3 (1980) 269-273
56. Johanson C.E., and Uhlenhuth E.H. Drug preference and mood in humans: d-amphetamine. Psychopharmacology 71 3 (1980) 275-279
57. Johnson R.E., Jaffe J.H., and Fudala P.J. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 267 (1992) 2750-2755
58. Johnson F., Sun S., Stauffer J., and Wagner G. Morphine release profile in a formulation containing polymer-coated extended-release morphine sulfate plus sequestered naltrexone. J. Pain 8 4 Suppl. 1 (2007) S40
59. Jones B.E., and Prada J.A. Drug-seeking behavior during methadone maintenance. Psychopharmacology 41 (1975) 7-10
60. Kampman K.M., Pettinati H., Lynch K.G., Sparkman T., and O'Brien C.P. A pilot trial of olanzapine for the treatment of cocaine dependence. Drug Alcohol Depend. 70 (2003) 265-273
61. Katz J.L. Models of relative reinforcing efficacy of drugs and their predictive utility. Behav. Pharmacol. 1 4 (1990) 283-301
62. Katz N.P., Adams E.H., Chilcoat H., Colucci R.D., Comer S.D., Goliber P., Grudzinskas C., Jasinski D., Lande S.D., Passik S.D., Schnoll S.H., Sellers E., Travers D., and Weiss R. Challenges in the development of prescription opioid abuse-deterrent formulations. Clin. J. Pain 23 8 (2007) 648-660
63. Kirchmayer U., Davoli M., Verster A., Amato L., Feri M., and Perucci C.A. A systematic review on the efficacy of naltrexone maintenance treatment in opioid dependence. Addiction 97 (2002) 1241-1249
64. Kleven M.S., and Woolverton W.L. Effects of continuous infusions of SCH 23390 on cocaine- or food-maintained behavior in rhesus monkeys. Behav. Pharmacol. 1 (1990) 365-373
65. Lamb R.J., Preston K.L., Schindler C.W., Meisch R.A., Davis F., Katz J.L., Henningfield J.E., and Goldberg S.R. The reinforcing and subjective effects of morphine in post-addicts: a dose-response study. J. Pharmacol. Exp. Ther. 259 (1991) 1165-1173
66. Liguori A., Hughes J.R., and Oliveto A.H. Caffeine self-administration in humans. 1. Efficacy of cola vehicle. Exp. Clin. Psychopharmacol. 5 3 (1997) 286-294
67. Lile J.A., Stoops W.W., Allen T.S., Glaser P.E.A., Hays L.R., and Rush C.R. Baclofen does not alter the reinforcing, subject-rated or cardiovascular effects of intranasal cocaine in humans. Psychopharmacology 171 (2007) 441-449
68. Lile J.A., Stoops W.W., Glaser P.E.A., Hays L.R., and Rush C.R. Acute administration of the GABA reuptake inhibitor tiagabine does not alter the effects of oral cocaine in humans. Drug Alcohol Depend. 76 1 (2004) 81-91
69. Ling W., and Wesson D.R. Clinical efficacy of buprenorphine: comparison to methadone and placebo. Drug Alcohol Depend. 70 Suppl. 2 (2003) S49-S57
70. Little C., and Correia C.J. Use of a multiple-choice procedure with college student drinkers. Psychol. Addict. Behav. 20 4 (2006) 445-452
71. Madras B.K., Xie Z., Lin Z., Jassen A., Panas H., Lynch L., Johnson R., Livni E., Spencer T.J., Bonab A.A., Miller G.M., and Fischman A.J. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J. Pharmacol. Exp. Ther. 319 (2006) 561-569
72. Martinez D., Broft A., Foltin R.W., Slifstein M., Hwang D.-R., Huang Y., Perez A., Frankel W.G., Cooper T., Kleber H.D., Fischman M.W., and Laruelle M. Cocaine dependence and D2 receptor availability in the functional subdivisions of the striatum: Relationship with cocaine-seeking behavior. Neuropsychopharmacology 29 6 (2004) 1190-1202
73. McColl S., and Sellers E.M. Research design strategies to evaluate the impact of formulations on abuse liability. Drug Alcohol Depend. 83S (2006) S52-S62
74. Mello N.K., and Mendelson J.H. Buprenorphine suppresses heroin use by heroin addicts. Science 207 (1980) 657-659
75. Mello N.K., Mendelson J.H., Kuehnle J.C., and Sellers M.S. Operant analysis of human heroin self-administration and the effects of naltrexone. J. Pharmacol. Exp. Ther. 216 (1981) 45-54
76. Mello N.K., Mendelson J.H., and Kuehnle J.C. Buprenorphine effects on human heroin self-administration: an operant analysis. J. Pharmacol. Exp. Ther. 223 (1982) 30-39
77. Mendelson J.H., and Mello N.K. Experimental analysis of drinking behavior of chronic alcoholics. Ann. NY Acad. Sci. 133 (1966) 828-845
78. Mendelson J., Jones R.T., Welm S., Baggott M., Fernandez I., Melby A.K., and Nath R.P. Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers. Psychopharmacology (Berl) 141 1 (1999) 37-46
79. Meyer R.E., McNamee H.B., Mirin S.M., and Altman J.L. Analysis and modification of opiate reinforcement. Int. J. Addict. 11 (1976) 467-484
80. Mooney M., Green C., and Hatsukami D. Nicotine self-administration: cigarette versus nicotine gum diurnal topography. Hum. Psychopharmacol. Clin. Exp. 21 (2006) 539-548
81. 1/5 antagonist, ecopipam, fails to attenuate the subjective and physiological effects of cocaine. Psychopharmacology 155 (2001) 338-347
82. O'Brien C.P., and Gardner E.L. Critical assessment of how to study addiction and its treatment: human and non-human animal models. Pharmacol. Ther. 108 (2005) 18-58
83. Panlilio L.V., and Goldberg S.R. Self-administration of drugs in animals and humans as a model and an investigative tool. Addiction 102 (2007) 1863-1870
84. Preston K.L., and Jasinski D.R. Abuse liability studies of opioid agonist-antagonists in humans. Drug Alcohol Depend. 28 (1991) 49-82
85. Preston K.L., and Walsh S.L. Evaluating abuse liability: methods and predictive value. In: Karch S.B. (Ed). Drug Abuse Handbook (1998), CRC Press, Boca Raton, FL 276-306
86. Richter K.P., Hamilton A.K., Hall S., Catley D., Cox L.S., and Grobe J. Patterns of smoking and methadone dose in drug treatment patients. Exp. Clin. Psychopharmacol. 15 (2007) 144-153
87. Roehrs T., Pedrosi B., Rosenthal L., Zorick F., and Roth T. Hypnotic self-administration: forced-choice versus single-choice. Psychopharmacology 133 (1997) 121-126
88. Roset P.N., Farre N., de la Torre R., Mas M., Menoyo E., Hernandez C., and Cami J. Modulation of rate of onset and intensity of drug effects reduces abuse potential in healthy males. Drug Alcohol Depend. 64 3 (2001) 285-298
89. Rowlett J.K. A labor-supply analysis of cocaine self-administration under progressive-ratio schedules: antecedents, methodologies, and perspectives. Psychopharmacology 153 (2000) 1-16
90. Rukstalis M., Jepson C., Strasser A., Lynch K.G., Perkins K., Patterson F., and Lerman C. Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm. Psychopharmacology 180 1 (2005) 41-48
91. Schuster C.R. Drugs as reinforcers in monkeys and man. Pharmacol. Rev. 27 4 (1976) 511-521
92. Skinner B.F. What is the experimental analysis of behavior?. J. Exp. Anal. Behav. 9 (1966) 213-218
93. Sofuoglu M., Pentel P.R., Bliss R.L., Goldman A.I., and Hatsukami D.K. Effects of phenytoin on cocaine self-administration in humans. Drug Alcohol Depend. 53 3 (1999) 273-275
94. Spiga R., Schmitz J., and Day J. Effects of nicotine on methadone self-administration in humans. Drug Alcohol Depend. 50 (1998) 157-165
95. Stafford D., LeSage M.G., and Glowa J.R. Progressive-ratio schedules of drug delivery in the analysis of drug self-administration: a review. Psychopharmacology 139 (1998) 169-184
96. Stern K.N., Chait L.D., and Johanson C.E. Reinforcing and subjective effects of oral tripelennamine in normal human volunteers. Behav. Pharmacol. 1 2 (1989) 161-167
97. Stitzer M.L., McCaul M.E., Bigelow G.E., and Liebson I.A. Oral methadone self-administration: effects of dose and alternative reinforcers. Clin. Pharmacol. Ther. 34 1 (1983) 29-35
98. Stoller K.B., Bigelow G.E., Walsh S.L., and Strain E.C. Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology 154 3 (2001) 230-242
99. Strain E.C. Clinical use of buprenorphine. In: Stitzer M., and Strain E.C. (Eds). The Treatment of Opioid Dependence. 2nd Edition (2006), The Johns Hopkins University Press, Baltimore 230-252
100. Strain E.C., Bigelow G.E., Liebson I.A., and Stitzer M.L. Moderate- vs. high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA 281 (1999) 1000-1005
101. Stoops W.W., Vansickel A.R., Lile J.A., and Rush C.R. Acute d-amphetamine pretreatment does not alter stimulant self-administration in humans. Pharmacol. Biochem. Behav. 87 1 (2007) 20-29
102. Substance Abuse and Mental Health Services Administration (SAMHSA), 2007. Office of Applied Studies. Results from the 2006 National Survey on Drug Use and Health: National Findings (Office of Applied Studies, NSDUH Series H-32, DHHS Publication No. SMA 07-4293). Rockville, MD.
103. Sullivan M.A., Comer S.D., and Nunes E. Pharmacology and clinical use of naltrexone. In: Stitzer M., and Strain E.C. (Eds). The Treatment of Opioid Dependence. 2nd Edition (2005), The Johns Hopkins University Press, Baltimore 295-320
104. Sullivan M.A., Vosburg S.K., and Comer S.D. Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin. Psychopharmacology 189 (2006) 37-46
105. Tancer M., and Johanson C.E. Reinforcing, subjective and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP. Drug Alcohol Depend. 72 1 (2003) 33-44
106. Tancer M., and Johanson C.E. The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 189 (2007) 565-573
107. Thompson T., and Schuster C.R. Morphine self-administration, food-reinforced and avoidance behaviors in rhesus monkeys. Psychopharmacology 5 (1964) 87-94
108. Vocci F.J., and Elkashef A. Pharmacotherapy and other treatments for cocaine abuse and dependence. Curr. Opin. Psychiatry 18 (2005) 265-270
109. Walsh S.L., Preston K.L., Bigelow G.E., and Stitzer M.L. Acute administration of buprenorphine in humans: partial agonist and blockade effects. J. Pharmacol. Exp. Ther. 274 (1995) 361-372
110. Walsh S.L., Sullivan J.T., Preston K.L., Garner J.E., and Bigelow G.E. Effects of naltrexone on response to intravenous cocaine, hydromorphone, and their combination in humans. J. Pharmacol. Exp. Ther. 279 (1996) 524-538
111. Walsh S.L., and Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend. 70 (2003) S13-S27
112. Walsh S.L., Geter-Douglas B., Strain E.C., and Bigelow G.E. Enadoline and butorphanol: Evaluation of κ agonists on cocaine pharmacodynamics and cocaine self-administration in humans. J. Pharmacol. Exp. Ther. 299 (2001) 147-158
113. Weinhold L.L., Preston K.L., Farre M., Liebson I.A., and Bigelow G.W. Buprenorphine alone and in combination with naloxone in non-dependent humans. Drug Alcohol Depend. 30 (1992) 263-274
114. World Drug Report, 2005. Volume 1: Analysis. United Nations Office on Drugs and Crime. United Nations Publication Sales No. E.05.XI.10 ISBN 92-1-148200-3, pp.39-79.
115. Wright C., Kramer E.D., Zalman M.A., Smith M.Y., and Haddox J.D. Risk identification, risk assessment, and risk management of abusable drug formulations. Drug Alcohol Depend. 83S (2006) S68-S76
116. Zacny J., Bigelow G., Compton P., Foley K., Iguchi M., and Sannerud C. College on problems of drug dependence taskforce on prescription opioid non-medical use and abuse: position statement. Drug Alcohol Depend. 69 (2003) 215-232